menu
    • menu

    Company profile for Bright Peak Therapeutics

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Willow Birch Pharma delivers trusted, high-quality APIs nationwide with unmatched service, compliance, and competitive value.

    Virtual Booth

    Contact Supplier

    AMI Lifesciences is Driven by Chemistry. Powered by People.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Bright Peak is developing next-generation engineered cytokines for immuno-oncology indications

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Bright Peak TherapeuticsSwitzerland Flag
    Country
    Country
    Switzerland
    Address
    Address
    Aeschenvorstadt 36 Basel, Switzerland CH-4051
    Telephone
    Telephone
    +41 61 225 46 00
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.versantventures.com/portfolio/brightpeak-therapeutics
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Bright Peak Therapeutics Appoints John Schmid to Board
    Bright Peak Therapeutics Appoints John Schmid to Board

    17 Apr 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/04/17/3063247/0/en/Bright-Peak-Therapeutics-Appoints-John-Schmid-to-its-Board-of-Directors.html

    GLOBENEWSWIRE
    17 Apr 2025
    Share Share
    Bright Peak to Participate in 43rd Annual J.P. Morgan Conference
    Bright Peak to Participate in 43rd Annual J.P. Morgan Conference

    06 Jan 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/01/06/3004902/0/en/Bright-Peak-Therapeutics-to-Participate-in-43rd-Annual-J-P-Morgan-Healthcare-Conference.html

    GLOBENEWSWIRE
    06 Jan 2025
    Share Share
    Bright Peak Therapeutic Present Data at 2024 Annual Meeting of SITC
    Bright Peak Therapeutic Present Data at 2024 Annual Meeting of SITC

    08 Nov 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/11/08/2977559/0/en/Bright-Peak-Therapeutics-Presents-New-Data-at-the-2024-Annual-Meeting-of-the-Society-for-Immunotherapy-of-Cancer-SITC.html

    GLOBENEWSWIRE
    08 Nov 2024
    Share Share
    Bright Peak Doses First Patient In Phase 1/2a Trial Of BPT567
    Bright Peak Doses First Patient In Phase 1/2a Trial Of BPT567

    17 Oct 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/10/17/2964792/0/en/Bright-Peak-Therapeutics-Announces-Dosing-of-First-Patient-in-Phase-1-2a-Clinical-Trial-of-BPT567-a-First-in-Class-Bifunctional-PD1-IL18-Immunoconjugate.html

    GLOBENEWSWIRE
    17 Oct 2024
    Share Share
    J&J-backed Bright Peak secures $90m to advance immunoconjugate programme
    J&J-backed Bright Peak secures $90m to advance immunoconjugate programme

    11 Jun 2024

    // Robert Barrie PHARMACEUTICAL TECHNOLOGY

    https://www.pharmaceutical-technology.com/news/jj-backed-bright-peak-secures-90m-to-advance-immunoconjugate-programme/

    Robert Barrie PHARMACEUTICAL TECHNOLOGY
    11 Jun 2024
    Share Share
    Bright Peak Therapeutics Announces $90 Million in Series C Financing
    Bright Peak Therapeutics Announces $90 Million in Series C Financing

    11 Jun 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/06/11/2896527/0/en/Bright-Peak-Therapeutics-Announces-90-Million-in-Series-C-Financing-to-Advance-First-in-Class-PD1-IL18-Immunoconjugate-Program-Into-Clinical-Trials.html

    GLOBENEWSWIRE
    11 Jun 2024
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search